Roivant dis­cussing sale of its Pfiz­er-part­nered UC drug to Roche for $7B, ac­cord­ing to re­port

Roivant is in dis­cus­sions with Roche to sell its ex­per­i­men­tal ul­cer­a­tive col­i­tis drug for sev­er­al bil­lion dol­lars, less than a year af­ter ac­quir­ing the pro­gram from Pfiz­er, ac­cord­ing to a Thurs­day re­port from the Wall Street Jour­nal. 

The drug, known as RVT-3101 and po­si­tioned as a po­ten­tial block­buster, could fetch more than $7 bil­lion in a deal, the WSJ said. The re­port said a trans­ac­tion could be an­nounced short­ly, though it wasn’t fi­nal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER